Navigation Links
Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee

- Pain Reductions Observed at Eight Weeks Sustained up to 12 Weeks and Drug Remains Very Well Tolerated -

SOUTH SAN FRANCISCO, Calif., July 02, 2007 /PRNewswire-FirstCall/ -- Anesiva, Inc. today announced preliminary longer-term, follow-up results from a Phase 2 study showing that a 1mg treatment with Adlea(TM) (formerly 4975) in patients with moderate-to-severe osteoarthritis of the knee produced substantial reductions in pain that persisted for up to 12 weeks.

"The positive preliminary results from this knee pain study further strengthen our belief that Adlea will prove to be a safe and effective drug in multiple osteoarthritis indications," said John P. McLaughlin, chief executive officer of Anesiva. "We are on-track to advance Adlea into late-stage trials in various indications this summer, including a Phase 2/3 trial for osteoarthritis of the knee."

Fifty-five patients with osteoarthritis of the knee were randomized to receive either: (I) a single injection of 1 mg of Adlea (n=36) or (II) three stepped ascending weekly doses totaling 1 mg of Adlea (n=19). At baseline prior to treatment, approximately three quarters of the patients had moderate pain while the other quarter had severe or extreme pain. As was previously reported, patients treated with Adlea demonstrated a 61 percent reduction in mean pain intensity from baseline to week one, and the analgesic effect was sustained at all subsequent weeks to the last scheduled in-clinic assessment at week eight, at which time a 64 percent reduction in pain from baseline was reported. At week 12, pain reductions were sustained. A cohort of 50 patients showed a 65 percent reduction from baseline pain scores. Forty two percent of the patients reported "no pain," 44 percent had "mild pain," and only 14 percent reported "moderate" or "severe" pain. The lengthy duration of clinical benefit is consistent with the known mechanism of action that suggests treatment with Adlea administered as a single injectio
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/24/2013)... LOS ANGELES , May 24, 2013  An ... gathered on Saturday, May 18, in Santa ... findings on new lung-sparing therapies for MPM, a rare ... and commonly affects the pleura, the lining of the ... Heart, Lung and Blood Institute, the 3rd Annual International ...
(Date:5/24/2013)... 24, 2013 In accordance with Rule 17.1 and ... of the United States Exchange Act, Echo Pharma Acquisition Limited ... Elan Corporation (NYSE: ELN). Background On ... an offer for the entire of the issued and to ... "Original Offer").  On 20 May 2013, Royalty ...
(Date:5/23/2013)... 24, 2013 3SBio Inc. (NASDAQ: ... leading China -based biotechnology company ... products, announced today that, at an extraordinary general ... voted in favor of the proposal to authorize ... of merger dated February 8, 2013, among Decade ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 93SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... , GLENVIEW, Ill. , Feb. 11 ... to announce the recipients of this year,s Presidential Commendations and Awards ... Gallagher , MD, MPH . This year,s recipients were recognized at ... week, where more than 800 scientists and physicians convened to learn ...
... , , NEW YORK , Feb. 11 ... telecommunication firms are strategically poised to capitalize on rapid ... are increasingly looking for innovative ways to collaborate with ... patients. Despite near universal agreement among pharmaceutical industry executives ...
Cached Medicine Technology:The American Academy of Pain Medicine Announces this Year's Presidential Commendations and Awards 2The American Academy of Pain Medicine Announces this Year's Presidential Commendations and Awards 3The American Academy of Pain Medicine Announces this Year's Presidential Commendations and Awards 4Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds 2Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds 3Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds 4Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds 5
(Date:5/25/2013)... (PRWEB) May 25, 2013 On May 20, ... people do not wish to discuss or plan for their ... FuneralFinancials.com released a Must-Do List to help ... Funeral Financials recommends, “Creating a personal fact sheet.” , While ... organize financial information and personal data. It may include ...
(Date:5/25/2013)... NY (PRWEB) May 25, 2013 On ... to brain cancer research and advocacy, comments on a ... Physics, that shows incorporating cold atmospheric plasma into brain ... , According to a Science Daily ... Physics (MPE), biologists and physicians demonstrated the “synergistic effect ...
(Date:5/25/2013)... According to world-renowned scholars, Queen Cleopatra VII ... that ever lived. Cleopatra’s legendary beauty moved nations and ... powerful men in her time. Cleopatra was also a ... skin glowing and fresh, from her legendary milk baths ... and cyprus grass. , Cleopatra was said to possess ...
(Date:5/25/2013)... Prairie Living at Chautauqua , a BMA ... Cross Blood Drive from 1:30 to 5:30 p.m. on ... at 955 Villa Ct. in Carbondale, Illinois, serves older ... need some help to maintain their independence.. , "Come ... Frey, Director of Marketing for Prairie Living. , For ...
(Date:5/25/2013)... 25, 2013 Superior Magnetics for Pain ... in seconds for arthritis, tendinitis and bursitis , Pain ... relief products announced a magnetic bracelet so ... for pain relief is demonstrated at fairs and festivals. ... Gauss magnets and has customers often report pain relief ...
Breaking Medicine News(10 mins):Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2Health News:Magnetic bracelet relieves pain in seconds announces Superior Magnetics 2
... Dietary Supplement, a product containing the drug estazolam, which might ... few months. // ,Estazolam belongs to benzodiazepines class ... prescription as it may have a number of side effects ... it is not legal to sell it in Canada. ...
... has been a major outbreak of pneumonia in the Downtown ... ,The outbreak in the Downtown Eastside has clearly ... ,In a November 30 memo, David Butcher, vice-president ... that the Vancouver outbreak was severely limiting the availability of ...
... weekend night over, ice has become an integral part of the ... used by people along with ice are marijuana, ketamine, heroin and ... the effects of these drugs when they have report to work. ... sensation in my head, after which they usually smoke ice to ...
... two different proteins taken from primary tumor biopsies is ... lymph nodes, according to researchers who// say this protein ... patients whose disease is likely to metastasize. ... researchers say over-expression of one unidentified protein and under-expression ...
... of senior scientists warns that many tests of drugs on animals// ... will work on humans. ,The British Medical Journal (BMJ) ... that animal studies agreed with human trials in just three areas ... high-profile London drug trial that left six men ill early this ...
... people with history of unprotected sex to have an ... transmission.// The announcement being the first case of such ... Thursday uncovered two clusters of HIV infections, HIV-1 subtype ... government scientists. They said that both the clusters found ...
Cached Medicine News:Health News:Researchers Find Two Biomarkers With Potential to Predict Breast Cancer Spread 2Health News:Researchers Find Two Biomarkers With Potential to Predict Breast Cancer Spread 3Health News:Researchers Find Two Biomarkers With Potential to Predict Breast Cancer Spread 4Health News:Many Drug Tests on Animals are Badly Flawed, a Study Warns 2
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
Sandhill Scientific offers a comprehensive selection of solid state and water perfused catheters for both adult & pediatric applications.Contact Sandhill Scientific for full details...
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator....
Medicine Products: